Health Care | Health Care Equipment & Services | Health Care Providers & Services |
NASDAQ | Common Stock
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China.
The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services.
Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells.
It is also developing RNA-based FASH-CARTM cell therapy platform.
In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited.
Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry.
The company is headquartered in Freehold, New Jersey.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 14, 22 | -0.06 Decreased by -200.00% | - |
| Aug 5, 22 | -0.02 Increased by +33.33% | - |
| May 11, 22 | -0.02 Increased by +33.33% | - |
| Mar 30, 22 | -0.03 Increased by +25.00% | - |
| Nov 15, 21 | -0.02 Increased by +50.00% | - |
| Aug 16, 21 | -0.03 Increased by +25.00% | - |
| May 14, 21 | -0.03 Increased by +57.14% | - |
| Mar 30, 21 | -0.04 Increased by +6.10% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 22 | 317.39 K Decreased by -34.80% | -5.41 M Decreased by -167.47% | Decreased by -1.71 K% Decreased by -310.20% |
| Jun 30, 22 | 290.82 K Increased by +3.78% | -2.03 M Increased by +14.23% | Decreased by -697.50% Increased by +17.35% |
| Mar 31, 22 | 297.63 K Increased by +2.71% | -2.07 M Increased by +12.53% | Decreased by -695.67% Increased by +14.84% |
| Dec 31, 21 | 334.20 K Decreased by -26.48% | -2.33 M Decreased by -75.19 K% | Decreased by -698.46% Decreased by -102.30 K% |
| Sep 30, 21 | 486.76 K Increased by +49.78% | -2.02 M Increased by +37.75% | Decreased by -415.85% Increased by +58.44% |
| Jun 30, 21 | 280.23 K Decreased by -6.98% | -2.36 M Increased by +22.62% | Decreased by -843.91% Increased by +16.82% |
| Mar 31, 21 | 289.77 K Decreased by -39.53% | -2.37 M Increased by +56.56% | Decreased by -816.88% Increased by +28.16% |
| Dec 31, 20 | 454.56 K Decreased by -5.14% | -3.10 K Increased by +99.94% | Decreased by -0.68% Increased by +99.94% |